Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 2/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | CASP2 | P42575 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | F13A1 | P00488 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA6 | P23280 | 2/20 | 0.39 |
| ▸ | CA5A | P35218 | 2/20 | 0.39 |
| ▸ | THPO | P40225 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Motuporamine C SCHEMBL6511891 | 1.00 | SCN5A (0.46) | SCN5AACE2HRH3KDM1ACASP2 | |
| SCHEMBL6509654 | 0.98 | SCN5A (0.44) | SCN5AACE2HRH3KDM1ACASP2 | |
| SCHEMBL15295963 | 0.98 | SCN5A (0.44) | SCN5AACE2HRH3KDM1ACASP2 | |
| SCHEMBL6505149 | 0.95 | SCN5A (0.43) | SCN5AACE2HRH3KDM1ACASP2 | |
| SCHEMBL6506342 | 0.89 | ACE2 (0.54) | SCN5AACE2HRH3KDM1ACASP2 | |
| SCHEMBL4361290 | 0.89 | ACE2 (0.54) | SCN5AACE2HRH3KDM1ACASP2 | |
| SCHEMBL15295964 | 0.89 | ACE2 (0.54) | SCN5AACE2HRH3KDM1ACASP2 | |
| SCHEMBL6510779 | 0.89 | ACE2 (0.54) | SCN5AACE2HRH3KDM1ACASP2 | |
| SCHEMBL10939162 | 0.88 | ACE2 (0.56) | SCN5AACE2HRH3CASP2CA12 | |
| SCHEMBL10936965 | 0.84 | ACE2 (0.57) | SCN5AACE2HRH3CASP2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 800 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090640-B2 | Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof | WAKE FOREST UNIVERSITY | 2015-07-28 | — | — | US | claimed |
| US-8906896-B2 | Platinum acridine anti-cancer compounds and methods thereof | WAKE FOREST UNIVERSITY | 2014-12-09 | — | — | US | claimed |
| US-20140193334-A1 | Targeted Delivery and Prodrug Designs for Platinum-Acridine Anti-Cancer Compounds and Methods Thereof | WAKE FOREST UNIVERSITY | 2014-07-10 | — | — | US | claimed |
| WO-2013033430-A1 | TARGETED DELIVERY AND PRODRUG DESIGNS FOR PLATINUM-ACRIDINE ANTI-CANCER COMPOUNDS AND METHODS THEREOF | WAKE FOREST SCHOOL OF MEDICINE (US) | 2013-03-07 | — | — | WO | claimed |
| US-20120039800-A1 | Platinum Acridine Anti-Cancer Compounds And Methods Thereof | WAKE FOREST UNIVERSITY | 2012-02-16 | — | — | US | claimed |
| EP-2358203-A1 | PLATINUM ACRIDINE ANTI-CANCER COMPOUNDS AND METHODS THEREOF | Wake Forest University (US) | 2011-08-24 | — | — | EP | claimed |
| WO-2010048499-A1 | PLATINUM ACRIDINE ANTI-CANCER COMPOUNDS AND METHODS THEREOF | WAKE FOREST UNIVERSITY (US) | 2010-04-29 | — | — | WO | claimed |
| US-20090326056-A1 | NOVEL ACTIVES AGAINST PROSTATE CARCINOMA | DSM IP ASSETS B.V. (NL) | 2009-12-31 | — | — | US | claimed |
| EP-1569628-B1 | NOVEL USE OF LYCOPENE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ANDROGEN SIGNALLING | DSM IP ASSETS BV (NL) | 2009-07-22 | — | — | EP | claimed |
| CN-101442995-A | Novel actives against prostate carcinoma | DSM IP ASSETS BV (NL) | 2009-05-27 | — | — | CN | claimed |
| WO-2007131767-A2 | NOVEL ACTIVES AGAINST PROSTATE CARCINOMA | DSM IP ASSETS B.V. (NL) | 2007-11-22 | — | — | WO | claimed |
| US-20060069151-A1 | Novel use of lycopene | DSM IP ASSETS B.V. (NL) | 2006-03-30 | — | — | US | claimed |
| US-20060020046-A1 | Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies | DMS IP ASSETS B.V. (NL) | 2006-01-26 | — | — | US | claimed |
| CN-1720030-A | The new purposes of lycopene | DSM IP ASSETS BV (NL) | 2006-01-11 | — | — | CN | claimed |
| US-20050222126-A1 | Antiangiogenic compounds and an assay for inhibitors of cell invasion | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2005-10-06 | — | — | US | claimed |
| EP-1569628-A1 | NOVEL USE OF LYCOPENE | DSM IP Assets B.V. (NL) | 2005-09-07 | — | — | EP | claimed |
| CN-1649574-A | Compositions comprising lycopene for the treatment and prevention of angiogenesis-related pathologies | DSM IP ASSETS BV (NL) | 2005-08-03 | — | — | CN | claimed |
| EP-1476143-A1 | COMPOSITIONS COMPRISING LYCOPENE FOR THE TREATMENT AND PREVENTION OF ANGIOGENESIS ASSOCIATED PATHOLOGIES | DSM IP Assets B.V. (NL) | 2004-11-17 | — | — | EP | claimed |
| WO-2004052351-A1 | NOVEL USE OF LYCOPENE | DSM IP ASSETS B.V. (CH) | 2004-06-24 | — | — | WO | claimed |
| WO-2003068202-A1 | COMPOSITIONS COMPRISING LYCOPENE FOR THE TREATMENT AND PREVENTION OF ANGIOGENESIS ASSOCIATED PATHOLOGIES | DSM IP ASSETS B.V. (NL) | 2003-08-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039800-A1 | Platinum Acridine Anti-Cancer Compounds And Methods Thereof | ACR, TP53, BAD | SCN5A 3888/4885ACE2 3677/4885HRH3 1265/4885 |
| US-20140193334-A1 | Targeted Delivery and Prodrug Designs for Platinum-Acridine Anti-Cancer Compounds and Methods Thereof | ERBB3, EGFR, ESR1 | SCN5A 2240/4885ACE2 3749/4885HRH3 1272/4885 |
| US-20050222126-A1 | Antiangiogenic compounds and an assay for inhibitors of cell invasion | MKI67, FLT4, DCX | SCN5A 4193/4885ACE2 3397/4885HRH3 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.